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ABSTRACT 
 
OBJECTIVE: The objective of the selective EBM review is to determine whether or not, “Is 
curcumin effective at reducing pain in arthritis patients?” 
STUDY DESIGN: Review of three, double blind, randomized controlled trials (RCTs), 
published between 2012 and 2014, all in English language. The articles compared oral curcumin 
to visually matched placebo or accepted standard treatment. 
DATA SOURCES: Three RCTs were found using PubMed. All articles were published in peer-
reviewed journals and selected based on correlation to topic choice, date of publication, and 
evaluating POEMs. 
OUTCOMES MEASURED: Patient reported pain level, as measured by visual analog scale 
(VAS) score. 
RESULTS: All three studied demonstrated a statistically significant reduction in patients’ pain 
levels in the curcumin group versus the control group. Chandran et al reported a mean change in 
baseline pain of 59.9% in the curcumin group, as compared to 49.94% in control group. 
Nakagawa et al also demonstrated a statistically significant change in mean from baseline 
between curcumin treatment and placebo. Panahi et al similarly found a post-treatment reduction 
in VAS to be statistically significant between curcumin and placebo. 
CONCLUSION: Based off the data collected from the three RCTs, curcumin is effective in 
reducing arthritis pain in patients. 
KEY WORDS: curcumin, arthritis 
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INTRODUCTION 
 
 Osteoarthritis is a chronic degenerative condition of the joints that can cause disability 
and loss of function. Hallmarks of the condition include cartilage degeneration, increased 
subchondral thickness, osteophyte formation, and mild joint inflammation. The most common 
joints affected are knees, hips, interphalangeal joints and lumbosacral spine5. Rheumatoid 
arthritis is a systemic inflammatory disease characterized by synovitis in multiple joints9. This 
paper evaluates three randomized controlled trials (RCTs) comparing the efficacy of oral 
curcumin to placebo at reducing arthritis patients’ pain. 
 Currently 54.4 million United States adults have been diagnosed with a form of arthritis 
by a doctor. This represents 22.7% of the adult population of the country. The incidence is 
predicted to increase to 26% and by 2040 an estimated 78 million US adults will have a 
diagnosis of arthritis3. In 2003 arthritis accounted for $128 billion of health care costs4. Arthritis 
visits are extremely common in primary care and physician assistants are frequently responsible 
for management of the condition. Arthritis-related complaints account for over 100 million office 
visits each year1. 
 Risk factors for developing arthritis include joint injury, overuse, increased age, female 
gender, obesity, family history and race2. As the population ages and obesity affects more 
individuals the incidence of arthritis will continue to increase. Treatment for osteoarthritis 
includes non-pharmacologic measures such as physical therapy, exercise, joint unloading and 
weight loss. Pharmacologic therapies available are acetaminophen, oral or topical NSAIDs, 
topical capsaicin, intra-articular steroid injections or opioids. For advanced cases, surgical 
treatment such as joint replacement is indicated5. Rheumatoid arthritis treatments may include 
oral or intra-articular steroids and DMARDs such as methotrexate or TNF inhibitors9. A 
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concerning factor for treatment of arthritis is long term use of anti-inflammatory agents. Both 
osteoarthritis and rheumatoid arthritis have inflammatory components of the disease that 
contribute to pain. Risks of long term NSAID use include cardiovascular complications and 
gastrointestinal ulcers, while long term corticosteroid use carries significant complications of 
bone loss, cataracts and neurological changes. Due to the chronic nature of arthritis it is 
important to seek safer alternatives to current treatments, as well as evaluate add-on therapies. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not curcumin is 
effecting in reducing pain in arthritis patients. 
METHODS 
 Three randomized controlled trials were used in this review. Adults (over age 18) with 
osteoarthritis or rheumatoid arthritis comprise the population of the studies utilized. The 
experimental intervention was oral curcumin. Studies varied in dose of curcumin from 180 
mg/day to 1500 mg/day. The control group in Chandran et al study was given diclofenac sodium 
50 mg6. The control group in Nakagawa et al and Panahi et al received a visually-matched 
placebo pill6,7. The outcome evaluated in all three studies was a reduction in pain level, as 
demonstrated by VAS score. 
 All RCTs reviewed were published in peer-reviewed articles, written in English and 
found on the PubMed database. The keywords used in searches were “curcumin” and “arthritis.” 
The articles were chosen based on relevance to the objective and whether the outcome evaluated 
was a POEM. The inclusion criteria were randomized, controlled studies published within the 
last ten years. Exclusion criteria included patients under 18 years of age and disease-oriented 
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evidence. Reported statistics were mean change from baseline, p-value and independent samples 
t-test.  
Table 1: Demographics and Characteristics of Included Studies 
Study Type # 
Pts 
Age 
(yrs) 
Inclusion 
Criteria 
Exclusion Criteria W/D Interventions 
Chandran, 
2012 
RCT 45 18-
65 
RA 
diagnosis, 
RA 
functional 
class I/II, 
Disease 
activity 
score>5.1 
Concurrent treatment with 
NSAID/DMARD/anti-
TNF; Hgb <6.2, creatinine 
>1.4 mg/dL; bone/joint 
surgery within 8 weeks of 
screening or planned <12 
weeks after randomization; 
fibromyalgia dx; hx TB, 
uncontrolled DM, severe 
allergic reaction to 
medications; pregnant or 
nursing; hx of alcohol or 
drug abuse 
7 Curcumin 
BCM-95 
500mg 
Nakagawa, 
2014 
RCT 50 >40 Primary 
medial knee 
OA, 
Kellgren-
Lawrence 
grades II/III 
via xray 
Previous knee surgeries; 
knee injection during 
study; knee injection 
within 2 months of study; 
other steroids within 4 
weeks of study 
9 Theracurmin 
containing 
180 mg/day of 
curcumin  
Panahi, 
2014 
RCT 53 <80 Degenerative 
primary knee 
OA mild-
moderate 
severity; 
bilateral OA 
Allergy to curcuminoids; 
candidate for joint 
replacement; OA 
secondary to trauma; 
malabsorption disorders; 
ESR>20; heart/renal/liver 
failure; corticosteroid use 
above 10 mg/day in last 3 
months; history psych 
disorders; intra-articular 
injections within last 3 
months 
13 C3complex® 
1500mg/day 
with 5-mg 
Bioperine®  
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OUTCOMES MEASURED 
 The primary outcome measured in all three studies was change in visual activity scale 
score. The patient-oriented outcome addressed in all three studies is patients’ pain levels 
indicated by patient marking a line on a scale of 0 (no pain) to 100 (severe pain). Each study 
collected initial VAS scores prior to intervention and again after the trial.  
RESULTS 
 Two studies compared oral curcumin with placebo and one with oral curcumin vs. 
diclofenac (standard treatment)5,6,7. Panahi et al evaluated the intervention over 6 weeks, while 
both Chandran et al and Nakagawa et al evaluated over 8 weeks5,6,7. Chandran et al was a single-
blinded study, while both Nakagawa et al and Panahi et al were double-blinded5,6,7.  
The Chandran et al study was conducted in Karala, India and included patients age 18-65 
who have been diagnosed with rheumatoid arthritis and disease activity score greater than 5.16. 
Exclusion criteria for the study included recent treatment for RA, low hemoglobin, elevated liver 
enzymes, recent surgery, other significant rheumatologic disease, history of tuberculosis, 
pregnancy, and history of alcohol or drug abuse6. Chandran et al evaluated 45 patients randomly 
divided into three groups6. The first group received oral curcumin (500mg), the second received 
diclofenac sodium (50 mg) and the third received a combination over a period of 8 weeks6. Only 
the first two groups will be discussed in this review6. Of the initial 45 patients, 38 completed the 
study and the author did not report reasons for leaving the trial6. At the end of the trial patients 
reported their assessment of disease activity by visual analog scale (VAS) with 0 being no pain 
and 100 being severe pain. Chandran et al also evaluated patients’ vital signs and laboratory 
values bi-weekly for safety6. Results were calculated by change from baseline to endpoint and 
the curcumin group was found to have the highest reduction in VAS score6. An ANOVA test 
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was used to assess primary outcome of the trial between groups6. Within the groups an 
independent t-test was used to evaluate significance of change from baseline6. A significant p- 
value of <.05 was calculated for change from baseline for this group6. There was not a significant 
difference between curcumin and diclofenac pain reduction percentages, however this 
demonstrates similar efficacy to conventional NSAID treatment for rheumatoid arthritis6. The 
diclofenac group had the most adverse events, with three patients reporting side effects, while 
curcumin patients reported two adverse events (minor fever and throat infection)6.  
Table 2: Patient Outcomes as Evaluated by Mean Change in VAS in Chandran et al 
 Baseline End of Treatment p-value 
Curcumin 68.57r17.14 27.5r9.45 <.05 
Diclofenac 78.25r11.25 39.17r20.1 <.05 
 
Nakagara et al conducted their study in Japan and included 50 patients with primary 
medial knee osteoarthritis7. Exclusion criteria included previous knee surgeries, recent knee 
injections or recent steroid treatment7. Patients were randomly divided into two groups, the first 
of which received 180 mg of oral curcumin per day and the control received a visually-matched 
placebo7. Three subjects in total were lost to follow-up during the study (two from the curcumin 
group and one from the control) and three patients dropped out due to adverse effects7. Two 
patients in the curcumin group withdrew due to hypertension and redness of the tongue, while 
one in the control group felt unwell7. Patients were seen at weeks 2, 4, 6 and 8 for compliance 
checks. Patients gave an initial knee pain visual analog scale score and were re-evaluated at the 
8-week mark7. 41 patients in total were evaluated and those treated with curcumin had 
significantly decreases in their VAS scores from baseline versus the placebo group (p=.023)7. 
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The authors opted to exclude patients with low initial VAS scores (<.15) when evaluating the 
efficacy of the curcumin, as their pain level was already so low no significant change could be 
reported7. The authors were also able to verify the safety of the supplement by evaluating 
laboratory values on the patients throughout the study7.  
Panahi et al conducted a study in Tehran, Iran including 53 patients with primary 
degenerative knee osteoarthritis8. Exclusion criteria included allergy to curcuminoids, OA 
secondary to trauma, active inflammatory conditions, and heart, renal or liver failure8. Patients 
were randomly assigned to two groups where one group received curcuminoids 1500 mg/day and 
the other received a visually matched placebo8. 40 subjects completed the 6-week trial8. The 
remaining 13 patients were lost to follow up8. Patients were evaluated by change in VAS from 
baseline to end of treatment8. Panahi et al used paired samples t-tests to compare baseline versus 
end-trial values for each parameter8. The two groups were compared using independent samples 
t-test8. The authors found significant (p<.001) reduction in VAS score from baseline in the 
curcumin group, as well as in comparison to the placebo group8. There were no serious adverse 
events reported, only minor gastrointestinal symptoms with 7 patients in the curcumin group 
reporting these and 4 in the placebo cases (no significant difference between the groups)8.   
Table 3: Efficacy of Oral Curcumin in Treating Arthritis Pain  
 Comparison p-value 
Chandran et al Change from baseline <.05 
Nakgawa et al Placebo .023 
Panahi et al Placebo <.001 
 
DISCUSSION 
 Rheumatoid arthritis and osteoarthritis are both chronic degenerative conditions for 
which patients must be on long term treatments to control pain. The current trouble is that 
accepted treatments do not have safe profiles. Acetaminophen can cause liver toxicity, chronic 
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NSAID use is associated with ulcers and cardiovascular complications and steroids are 
associated with osteoporosis5.  
 Curcumin is a polyphenol extracted from turmeric. Turmeric has been used as a spice in 
food preparations for centuries and thus is recognized as safe7. The anti-inflammatory botanical 
inhibits mediators of the inflammatory response including cytokines, chemokines, adhesion 
molecules, COX-2 and tissue factor6.  
 Curcumin in available widely in the United States as a supplement. There is no insurance 
coverage and it has not been evaluated by the FDA for use as a treatment for arthritis. For highly 
concentrated curcumin formulas there is a significant cost to the patient. As it has not been 
evaluated in the United States, it is likely that medical practitioners in the country are not 
familiar with the treatment and thus are not likely to recommend curcumin to their arthritis 
patients.  
 The three studies considered in this review all indicate that curcumin is an effective 
treatment for arthritis pain, as evidenced by patient’s reported VAS score. Chandran et al 
demonstrates similar efficacy between curcumin and diclofenac in rheumatoid arthritis patients, 
which is encouraging since diclofenac is an accepted treatment for pain5. Both Nakagara et al 
and Panahi et al relay information compared to placebo and note clinically significant 
improvement in osteoarthritis symptoms6,7. 
 While all three studies evaluated the effect of curcumin on a patient’s VAS score, 
Chandran et al only evaluated mean change from baseline. They evaluated curcumin and 
diclofenac separately and found similar reduction in pain levels between the groups but did not 
do a statistical analysis for the comparison5. Chandran et al was also the only study that was 
single-blinded5. Nakagawa et al and Panahi et al evaluated mean change and compared the two 
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groups to find a significant benefit in treatment with curcumin versus placebo6,7. Also, it should 
be noted that all three studies took place in Asia, so there warrants further testing in other 
countries. There are genetic components of both arthritis and metabolism of medications and 
supplements that could affect the efficacy of curcumin as a treatment. The duration of the three 
studies ranged from 6-8 weeks which is an acceptable length of time to evaluate how curcumin 
affects pain levels in arthritis patients, however it is not a significant amount of time to determine 
disease progression and long term effects of curcumin.  
  
CONCLUSION 
 The results of this review suggest that curcumin is a safe and effective treatment for 
arthritis. While all three studies reported a significant (p<.05) reduction in arthritis pain in 
patients treated with oral curcumin, the sample sizes were small5,6,7. It is also important to note 
that all took place in Asia, so there should be trials on other ethnicities to determine if the 
treatment is effective for the general population of the United States. The trials were of a short 
duration so longer studies would be important to conduct in the future that include radiologic 
evidence of changes in disease progression, as well as long term side effects of curcumin. In 
conclusion, the three trials evaluated in this review indicate curcumin is an effective treatment, 
but further evaluation with a larger sample size and longer duration trial is needed to fully 
determine the effectiveness of curcumin.  
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